Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy

World Journal of Urology

Volumn 21, Issue 4, 2003, Pages 275-289

  Collis, Spencer J ^a   Khater, Kevin ^a   DeWeese, Theodore L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE THERAPY; HUMAN; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; REVIEW;

COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 1542704139     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-003-0363-y     Document Type: Review

References (180)

1. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1690
2. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P (2002) Lentiviral-mediated RNA interference. Hum Gene Ther 13:2197-2201
3. Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, Miller M, Ely J, Gerlach W (1999) A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 10:2255-2270
4. Baker AM, Oberley LW, Cohen MB (1997) Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32:229-233
5. Barnett BG, Crews CJ, Douglas JT (2002) Targeted adenoviral vectors. Biochim Biophys Acta 1575:1-14
6. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480
7. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376
8. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, et al. (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:475-480
9. Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL (2002) Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther 13:627-639
10. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300
11. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103-106
12. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD (2000) Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 89:123-134
13. Boyer J, Rohleder K, Ketner G (1999) Adenovirus E4 34 k and E4 11 k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 263:307-312
14. Branch AD (1998) A good antisense molecule is hard to find. Trends Biochem Sci 23:45-50
15. Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095-1101
16. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6-13
17. Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T, He TC (2001) Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 1:149-162
18. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB (1996) An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814-3822
19. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416
20. Burton EA, Bai Q, Goins WF, Glorioso JC (2002) Replication-defective genomic herpes simplex vectors: design and production. Curr Opin Biotechnol 13:424-428
21. Burton EA, Fink DJ, Glorioso JC (2002) Gene delivery using herpes simplex virus vectors. DNA Cell Biol 21:915-936
22. Check E (2002) A tragic setback. Nature 420:116-118
23. Check E (2003) Cancer fears cast doubts on future of gene therapy. Nature 421:678
24. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf DB, Henderson DR, Yu DC (2001) CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 61:5453-5460
25. Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ, Woo S, Berner B, Smith EO, Oberg KC, Aguilar LK, Thompson TC, Butler EB, Aguilar-Cordova E (2001) Enhanced therapeutic effect of HSV-tk + GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 3:536-542
26. Cohen EE, Rudin CM (2001) ONYX-015. Onyx Pharmaceuticals. Curr Opin Invest Drugs 2:1770-1775
27. Colletier PJ, Ashoori F, Cowen D, Meyn RE, Tofilon P, Meistrich ME, Pollack A (2000) Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys 48:1507-1512
28. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP (2001) Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 29:1534-1538
29. Collis SJ, Ketner GW, Hicks JL, Nelson WG, Demarzo AM, Deweese TL (2003) Expression of the DNA-PK binding protein E4-34 K fails to confer radiation sensitivity to mammalian cells. Int J Radiat Biol 79:53-60
30. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL (2003) Enhanced Radiation and Chemotherapy-mediated Cell Killing of Human Cancer Cells by Small Inhibitory RNA Silencing of DNA Repair Factors. Cancer Res 63:1550-1554
31. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, Barrazza-Ortiz X, Adams R, Askin FB, Carter BJ, Guggino WB, Flotte TR (1996) Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 3:658-668
32. Cowen D, Salem N, Ashoori F, Meyn R, Meistrich ML, Roth JA, Pollack A (2000) Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res 6:4402-4408
33. Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, Fong Y (2002) Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 53:95-100
34. Dash P, Lotan I, Knapp M, Kandel ER, Goelet P (1987) Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci U S A 84:7896-7900
35. Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF (2002) rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res 62:3077-3083
36. Debbas M, White E (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7:546-554
37. Derossi D, Chassaing G, Prochiantz A (1998) Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 8:84-87
38. DeWeese TL, Shipman JM, Dillehay LE, Nelson WG (1998) Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J Urol 159:591-598
39. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW (2001) A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61:7464-7472
40. Dorai T, Perlman H, Walsh K, Shabsigh A, Goluboff ET, Olsson CA, Buttyan R (1999) A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer 82:846-852
41. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498
42. Epperly MW, Travis EL, Whitsett JA, Raineri I, Epstein CJ, Greenberger JS (2001) Overexpression of manganese superoxide dismutase (MnSOD) in whole lung or alveolar type II cells of MnSOD transgenic mice does not provide intrinsic lung irradiation protection. Int J Cancer 96:11-21
43. Epperly MW, Defilippi S, Sikora C, Gretton J, Greenberger JS (2002) Radioprotection of lung and esophagus by overexpression of the human manganese superoxide dismutase transgene. Mil Med 167:71-73
44. Epperly MW, Guo HL, Jefferson M, Nie S, Gretton J, Bernarding M, Bar-Sagi D, Archer H, Greenberger JS (2003) Cell phenotype specific kinetics of expression of intratracheally injected manganese superoxide dismutase-plasmid/ liposomes (MnSOD-PL) during lung radioprotective gene therapy. Gene Ther 10:163-171
45. Fan Z, Chakravarty P, Alfieri A, Pandita TK, Vikram B, Guha C (2000) Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Ther 7:1307-1314
46. Fichtinger G, DeWeese TL, Patriciu A, Tanacs A, Mazilu D, Anderson JH, Masamune K, Taylor RH, Stoianovici D (2002) System for robotically assisted prostate biopsy and therapy with intraoperative CT guidance. Acad Radiol 9:60-74
47. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021-1031
48. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K, Lu M, Aguilar-Cordova E, Kim JH (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62:4968-4976
49. Freytag SO, Paielli D, Wing M, Rogulski K, Brown S, Kolozsvary A, Seely J, Barton K, Dragovic A, Kim JH (2002) Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 54:873-885
50. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, Hilaris BS, Whitmore WF (1991) The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 21:537-547
51. Ghatak S, Ho SM (1996) Age-related changes in the activities of antioxidant enzymes and lipid peroxidation status in ventral and dorsolateral prostate lobes of noble rats. Biochem Biophys Res Commun 222:362-367
52. Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B (2002) Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev 21:79-92
53. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC (2003) Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 9:357-363
54. Greber UF, Willetts M, Webster P, Helenius A (1993) Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75:477-486
55. Greco O, Scott SD, Marples B, Dachs GU (2002) Cancer gene therapy: 'delivery, delivery, delivery'. Front Biosci 7:d1516-1524
56. Hammond SM, Caudy AA, Hannon GJ (2001) Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2:110-119
57. Hannon GJ (2002) RNA interference. Nature 418:244-251
58. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT (2003) Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63:847-853
59. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT (1999) In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10:1239-1249
60. Herweijer H, Wolff JA (2003) Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 10:453-458
61. Hock RA, Miller AD, Osborne WR (1989) Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 74:876-881
62. Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552-5555
63. Hope MJ, Mui B, Ansell S, Ahkong QF (1998) Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based druas (review). Mol Membr Biol 15:1-14
64. Hudson AJ, Normand N, Ackroyd J, Akhtar S (1999) Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int J Pharm 182:49-58
65. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP (1997) Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 89:1595-1601
66. Jansen B, Zangemeister-Wittke U (2002) Antisense therapy for cancer-the time of truth. Lancet Oncol 3:672-683
67. Jeggo PA, Taccioli GE, Jackson SP (1995) Menage a trois: double strand break repair, V(D)J recombination and DNA-PK. Bioessays 17:949-957
68. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A (2002) Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1:325-337
69. Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL (2001) Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 3:451-456
70. Kaiser J (2003) Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science 299:495
71. Kanai AJ, Zeidel ML, Lavelle JP, Greenberger JS, Birder LA, de Groat WC, Apodaca GL, Meyers SA, Ramage R, Epperly MW (2002) Manganese superoxide dismutase gene therapy protects against irradiation-induced cystitis. Am J Physiol Renal Physiol 283:F1304-1312
72. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, Takeuchi K, Kitamura K, Ichimura K, Ozawa K (2003) Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 10:51-58
73. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW (2003) Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 169:1122-1133
74. Kestin LL, Goldstein NS, Vicini FA, Mitchell C, Gustafson GS, Stromberg JS, Chen PY, Martinez AA (2002) Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 54:107-118
75. Kim DW, Andres ML, Li J, Kajioka EH, Miller GM, Seynhaeve AL, Ten Hagen TL, Gridley DS (2001) Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts. J Interferon Cytokine Res 21:885-897
76. Kim DW, Andres ML, Kajioka EH, Dutta-Roy R, Miller GM, Seynhaeve AL, ten Hagen TL, Gridley DS (2002) Modulation of innate immunological factors by STEALTH liposome-encapsulated tumor necrosis factor-alpha in a colon tumor xenograft model. Anticancer Res 22:777-788
77. Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A (2002) Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A 99:4708-4713
78. Kirn D (2001) Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 1:525-538
79. Kirn D (2001) Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8:89-98
80. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI (1990) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 87:2211-2215
81. Krasnykh V, Dmitriev I, Navarro JG, Belousova N, Kashentseva E, Xiang J, Douglas JT, Curiel DT (2000) Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res 60:6784-6787
82. Kuban DA, el-Mahdi AM, Schellhammer PF (1995) Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 75:2373-2382
83. Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, Chung LW (2003) Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14:227-241
84. Kunke D, Grimm D, Denger S, Kreuzer J, Delius H, Komitowski D, Kleinschmidt JA (2000) Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther 7:766-777
85. Lai CM, Lai YK, Rakoczy PE (2002) Adenovirus and adeno-associated virus vectors. DNA Cell Biol 21:895-913
86. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D (1991) Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187-192
87. Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, Jessup JM (2001) Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther 8:397-404
88. Lees-Miller SP, Long MC, Kilvert MA, Lam V, Rice SA, Spencer CA (1996) Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. J Virol 70:7471-7477
89. Levegrun S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC (2002) Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 63:11-26
90. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H (2002) Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32:107-108
91. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR (2001) A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 61:6428-6436
92. Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R (2002) Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res 62:2576-2582
93. Loimas S, Toppinen MR, Visakorpi T, Janne J, Wahlfors J (2001) Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy. Cancer Gene Ther 8:137-144
94. Mabjeesh NJ, Zhong H, Simons JW (2002) Gene therapy of prostate cancer: current and future directions. Endocr Relat Cancer 9:115-139
95. Marcellus RC, Lavoie JN, Boivin D, Shore GC, Ketner G, Branton PE (1998) The early region 4 orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis. J Virol 72:7144-7153
96. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP (2000) Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 7:511-517
97. Marples B, Greco O, Joiner MC, Scott SD (2002) Molecular approaches to chemo-radiotherapy. Eur J Cancer 38:231-239
98. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA (2002) RNA interference in adult mice. Nature 418:38-39
99. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61:8751-8757
100. McCormick F (2000) Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin Cancer Biol 10:453-459
101. Mesnil M, Yamasaki H (2000) Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 60:3989-3999
102. Mettlin CJ, Murphy GP, McDonald CJ, Menck HR (1999) The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer 86:1877-1882
103. Miller DG, Adam MA, Miller AD (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239-4242
104. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT (2000) Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 38:208-217
105. Mincheff M, Altankova I, Zoubak S, Tchakarov S, Botev C, Petrov S, Krusteva E, Kurteva G, Kurtev P, Dimitrov V, Ilieva M, Georgiev G, Lissitchkov T, Chernozemski I, Meryman HT (2001) In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol 39:125-132
106. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938-943
107. Miyake H, Chi KN, Gleave ME (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655-1663
108. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137-1143
109. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593
110. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F (2003) Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101:2563-2569
111. Myers KJ, Dean NM (2000) Sensible use of antisense: how to use oligonucleotides as research tools. Trends Pharmacol Sci 21:19-23
112. Nicklin SA, Baker AH (2002) Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther 2:273-293
113. Ohta Y, Kijima H, Ohkawa T, Kashani-Sabet M, Scanlon KJ (1996) Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res 24:938-942
114. Orlandi L, Binda M, Folini M, Bearzatto A, Villa R, Daidone MG, Zaffaroni N (2003) Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate 54:133-143
115. Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T (2000) Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. Jpn J Cancer Res 91:1339-1344
116. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16:948-958
117. Parkinson J, Lees-Miller SP, Everett RD (1999) Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol 73:650-657
118. Peng W, Verbitsky A, Bao Y, Sawicki J (2002) Regulated expression of diphtheria toxin in prostate cancer cells. Mol Ther 6:537-545
119. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS (2002) Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 62:6400-6404
120. Penichet ML, Kang YS, Pardridge WM, Morrison SL, Shin SU (1999) An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J Immunol 163:4421-4426
121. Peplinski GR, Tsung K, Norton JA (1998) Vaccinia virus for human gene therapy. Surg Oncol Clin N Am 7:575-588
122. Pierce ML, Ruffner DE (1998) Construction of a directed hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Res 26:5093-5101
123. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, et al. (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623
124. Pinski J, Parikh A, Bova GS, Isaacs JT (2001) Therapeutic implications of enhanced G(0)/G(1) checkpoint control-induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 61:6372-6376
125. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ (1999) Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis 2:S27
126. Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl R, Oberley TD (2003) Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. Oncogene 22:1024-1034
127. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen, II (2002) Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54:677-685
128. Quinonez R, Sutton RE (2002) Lentiviral vectors for gene delivery into cells. DNA Cell Biol 21:937-951
129. Raj K, Ogston P, Beard P (2001) Virus-mediated killing of cells that lack p53 activity. Nature 412:914-917
130. Rajcani J, Vojvodova A (1998) The role of herpes simplex virus glycoproteins in the virus replication cycle. Acta Virol 42:103-118
131. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E (1992) The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci U S A 89:7742-7746
132. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD, McCormick F (2002) Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 62:3812-3818
133. Richardson WD, Westphal H (1981) A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell 27:133-141
134. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antisen-positive prostate cancer cells. Cancer Res 57:2559-2563
135. Rodriguez R, Lim HY, Bartkowski LM, Simons JW (1998) Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics. Prostate 34:259-269
136. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH (2000) In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60:1193-1196
137. Sandberg JA, Parker VP, Blanchard KS, Sweedler D, Powell JA, Kachensky A, Bellon L, Usman N, Rossing T, Borden E, Blatt LM (2000) Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharmacol 40:1462-1469
138. Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, Matsuo M, Kamidono S, Gotoh A (2001) Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 51:1336-1345
139. Scanlon KJ, Ishida H, Kashani-Sabet M (1994) Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci U S A 91:11123-11127
140. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-1572
141. Scott SD, Marples B, Hendry JH, Lashford LS, Embleton MJ, Hunter RD, Howell A, Margison GP (2000) A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther 7:1121-1125
142. Scott SL, Higdon R, Beckett L, Shi XB, deVere White RW, Earle JD, Gumerlock PH (2002) BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm 17:647-656
143. Shen C, Buck AK, Liu X, Winkler M, Reske SN (2003) Gene silencing by adenovirus-delivered siRNA. FEBS Lett 539:111-114
144. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD (1999) Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281:1598-1604
145. Sischy B, Doggett RL, Krall JM, Taylor DG, Sause WT, Lipsett JA, Seydel HG (1989) Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst 81:850-856
146. Smalley SR, Kimler BF, Evans RG (1991) 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20:207-211
147. Smyth Templeton N (2002) Liposomal delivery of nucleic acids in vivo. DNA Cell Biol 21:857-867
148. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA (1999) Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 5:64-70
149. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, Gonen M, Fong Y (2002) Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 132:353-359
150. Stracker TH, Carson CT, Weitzman MD (2002) Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418:348-352
151. Suit HD, Westgate SJ (1986) Impact of improved local control on survival. Int J Radiat Oncol Biol Phys 12:453-458
152. Sweeney P, Pisters LL (2000) Ad5CMVp53 gene therapy for locally advanced prostate cancer-where do we stand? World J Urol 18:121-124
153. Taylor TJ, Brockman MA, McNamee EE, Knipe DM (2002) Herpes simplex virus. Front Biosci 7:d752-764
154. Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB (2001) Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-a preliminary report. Int J Radiat Oncol Biol Phys 51:605-613
155. Tekur S, Ho SM (2002) Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines. Mol Carcinog 33:44-55
156. ten Hagen TL, Seynhaeve AL, van Tiel ST, Ruiter DJ, Eggermont AM (2002) Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer 97:115-120
157. Thurman SA, Ramakrishna NR, DeWeese TL (2001) Radiation therapy for the treatment of locally advanced and metastatic prostate cancer. Hematol Oncol Clin North Am 15:423-443
158. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC (2003) Therapeutic targets for metastatic prostate cancer. Curr Drug Targets 4:251-261
159. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS (1996) The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70:2296-2306
160. Trezise AE (2002) In vivo DNA electrotransfer. DNA Cell Biol 21:869-877
161. Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL (2001) Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and non-human primates. Hum Gene Ther 12:999-1010
162. Varghese S, Rabkin SD (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9:967-978
163. Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010-16017
164. Vives E, Richard JP, Rispal C, Lebleu B (2003) TAT Peptide Internalization: Seeking the Mechanism of Entry. Curr Protein Pept Sci 4:125-132
165. Vorburger SA, Hunt KK (2002) Adenoviral gene therapy. Oncologist 7:46-59
166. Wadia JS, Dowdy SF (2003) Modulation of Cellular Function by TAT Mediated Transduction of Full Length Proteins. Curr Protein Pept Sci 4:97-104
167. Walder RY, Walder JA (1988) Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 85:5011-5015
168. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, Williams J (1997) Cell-cycle arrest versus cell death in cancer therapy. Nat Med 3:1034-1036
169. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10:2237-2243
170. Welch PJ, Barber JR, Wong-Staal F (1998) Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr Opin Biotechnol 9:486-496
171. Wong-Staal F, Poeschla EM, Looney DJ (1998) A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 9:2407-2425
172. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW (1993) Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53:3765-3770
173. Wybranietz WA, Gross CD, Phelan A, O'Hare P, Spiegel M, Graepler F, Bitzer M, Stahler P, Gregor M, Lauer UM (2001) Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 8:1654-1664
174. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S (2001) Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 8:628-635
175. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR (1999) The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 59:4200-4203
176. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J, Henderson DR (2001) Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 61:517-525
177. Zaloudik J, Li W, Jacob L, Kieny MP, Somasundaram R, Acres B, Song H, Zhang T, Li J, Herlyn D (2002) Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther 9:382-389
178. Zamore PD (2001) RNA interference: listening to the sound of silence. Nat Struct Biol 8:746-750
179. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8:3276-3284
180. Zeng M, Cerniglia GJ, Eck SL, Stevens CW (1997) High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther 8:1025-1032